Cargando…
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
Antibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope on the targeted cells. Trophoblast cell-surface antigen-2 (Trop-2) was originall...
Autores principales: | Vranic, Semir, Gatalica, Zoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860310/ https://www.ncbi.nlm.nih.gov/pubmed/34181512 http://dx.doi.org/10.17305/bjbms.2021.6100 |
Ejemplares similares
-
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023) -
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022) -
Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021) -
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022) -
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)